此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery?

2019年9月17日 更新者:Tae-Yop Kim, MD PhD、Konkuk University Medical Center

Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile and the Recovery of Hemoglobin in Total Knee and Hip Arthroplasty Surgery?

The objective of the present study is to determine the impact of intraoperative IV-iron supplementation on postoperative oxygenation profile by comparing the postoperative PaO2/FiO2 ratio with or without IV-iron supplementation in old patients undergoing elective uni-limb total knee arthroplasty surgery.

研究概览

详细说明

Participation and recruitment: Patients undergoing elective total knee arthroplasty due to osteoarthritis will be interviewed for participation and recruited after providing written informed consent.

Randomization and group allocation:

All recruited patients will be given patient identification number (PIN) for the present study of 01-77 according to their order of interview and recruitment.

Investigators will prepare 33 yellow and 34 green cards, which will be inserted in 77 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 77 (Envelop number).

After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department.

Preparation and Administration of study drug:

Pharmacist will open the envelope with the number same to PIN and check the color of the card inside at study on operation day.

According to the color of the card, IV-iron or placebo will be prepared for the patient: IV-iron for yellow card; placebo for green cards, respectively.

The study drug was employed as "open labelled".

IV-iron or placebo will be infused through already established intravenous line within 30 min after anesthesia induction by attending anesthesiologist who is aware of the patient's group-allocation.

Patient data and statistical analyses:

The information regarding the patient's group allocation will be kept in the pharmacy department till the end of the study and conveyed during the data analyses after completion of the 77th patient participation and discharge.

Patient's data PaO2, FiO2, Hb, intra-op and postop-transfusion amount, intraop- and postop-bleeding amount will be determined from the patients' medical record after patient's discharge.

All statistical analyses will be performed after the 77th patient's discharge and data acquisition.

Surgical procedures:

All surgical procedures will be performed using standardized institutional anesthetic and surgical protocols, antibiotic and antithrombotic prophylaxis, transfusion protocols, and post-operative analgesia.

All TKA will be performed using a pneumatic tourniquet, which is deflated after wound closure. Closed suction drains, which are removed on the second post-operative day, will be placed in all operations.

Transfusion protocol:

Following allogenic blood transfusion protocol will be uniformly applied by anesthesiologists and surgeons to all patients in the operating theater, the post-operative anesthesia care unit, and the ward for the entire duration of hospitalization: blood transfusion of packed RBC will not be performed unless patient's Hb level is < 9 g/dL without any signs and/or symptoms of acute anemia such as hypotension, tachycardia, tachypnea, dizziness, and fatigue.

研究类型

介入性

注册 (实际的)

76

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Seoul、大韩民国
        • Konkuk University Medical Center & Asan Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients with osteoarthritis in knee joint undergoing elective uni-limb total knee arthroplasty surgery
  • Patients provided a written informed consent.
  • Patients with s-ferritin < 300 mg/dl (male) or 200 mg/dl (female)
  • Patients with preoperative serum hemoglobin concentration >10 g/dL
  • Patients with PaO2/FiO2 ratio >150

Exclusion Criteria:

  • Patients with history of anaphylaxis, iron overload, active infection.
  • Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, recombinant human erythropoietin, or undergoing acute normovolemic hemodilution.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:控制组
安慰剂
麻醉诱导后给予安慰剂(生理盐水)
其他名称:
  • 生理盐水
实验性的:Experimental group
ferric carboxymaltose 1000 mg
Ferric carboxymaltose is administered after anesthesia induction
其他名称:
  • 铁注射液

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The changes of Hemoglobin between preoperative and postoperative day 30
大体时间:postoperative 30 days
intergroup-difference in hemoglobin change
postoperative 30 days
the changes of arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
大体时间:postoperative 5 days
intergroup-difference in PaO2/FiO2 ratio
postoperative 5 days

次要结果测量

结果测量
措施说明
大体时间
arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
大体时间:postoperative 1 day
intergroup-difference in PaO2/FiO2 ratio
postoperative 1 day
arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
大体时间:postoperative 3 days
intergroup-difference in PaO2/FiO2 ratio
postoperative 3 days
arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
大体时间:postoperative 5 days
intergroup-difference in PaO2/FiO2 ratio
postoperative 5 days
serum hemoglobin concentration
大体时间:postoperative 1 day
Intergroup difference of serum hemoglobin concentration, g/dL
postoperative 1 day
serum hemoglobin concentration
大体时间:postoperative 5 days
Intergroup difference of serum hemoglobin concentration, g/dL
postoperative 5 days
serum hemoglobin concentration
大体时间:postoperative 30 days
Intergroup difference of serum hemoglobin concentration, g/dL
postoperative 30 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年8月1日

初级完成 (实际的)

2018年12月1日

研究完成 (实际的)

2019年1月1日

研究注册日期

首次提交

2015年9月3日

首先提交符合 QC 标准的

2015年9月8日

首次发布 (估计)

2015年9月9日

研究记录更新

最后更新发布 (实际的)

2019年9月19日

上次提交的符合 QC 标准的更新

2019年9月17日

最后验证

2019年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • KonkukUMC

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅